



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION N	0.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/889,689		01/23/2002	Carlota Vinals-Bassols	BC45215	8665
25308	7590	03/09/2004		EXAM	NER
DECHERT ATTN: ALLEN BLOOM, ESQ 4000 BELL ATLANTIC TOWER 1717 ARCH STREET				SAKELARIS, SALLY A	
				ART UNIT	PAPER NUMBER
				1634	
PHILADELPHIA, PA 19103				DATE MAILED: 03/09/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	"	
	61.	`
	. ``	
•	\sim	
,	ヘル	

Office Action Summary

Application No.	Applicant(s)		
09/889,689	VINALS-BASSOLS, CARLOTA		
Examiner	Art Unit		
Sally A Sakelaris	1634		

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM

- Exte after - If the - If NC - Failu Any	MAILING DATE OF THIS COMMUNICATION. ensions of time may be available under the provisions of 37 CFR 1.136(a). In no ever SIX (6) MONTHS from the mailing date of this communication. The period for reply specified above is less than thirty (30) days, a reply within the state of period for reply is specified above, the maximum statutory period will apply and we ure to reply within the set or extended period for reply will, by statute, cause the appropriate of the period of the period for reply will, and the period of this content patent term adjustment. See 37 CFR 1.704(b).	tutory minimum of thirty (30) days will be considered timely. iill expire SIX (6) MONTHS from the mailing date of this communication.					
Status							
1)⊠	Responsive to communication(s) filed on 22 September 2	<u>2003</u> .					
2a) <u></u>	This action is FINAL . 2b) ☐ This action is r	on-final.					
3)	Since this application is in condition for allowance except	for formal matters, prosecution as to the merits is					
	closed in accordance with the practice under Ex parte Qu	uayle, 1935 C.D. 11, 453 O.G. 213.					
Disposit	tion of Claims						
4)🖂	Claim(s) 6-11 is/are pending in the application.						
	4a) Of the above claim(s) is/are withdrawn from co	nsideration.					
	Claim(s) is/are allowed.						
	Claim(s) is/are rejected.						
	Claim(s) is/are objected to.						
8)⊠	Claim(s) 6-11 are subject to restriction and/or election red	quirement.					
Applicati	ion Papers						
9)[The specification is objected to by the Examiner.						
10)	The drawing(s) filed on is/are: a) accepted or b)	objected to by the Examiner.					
	Applicant may not request that any objection to the drawing(s) to	e held in abeyance. See 37 CFR 1.85(a).					
_	Replacement drawing sheet(s) including the correction is requir	· ·					
11)	The oath or declaration is objected to by the Examiner. No	ote the attached Office Action or form PTO-152.					
Priority ι	under 35 U.S.C. § 119						
	Acknowledgment is made of a claim for foreign priority und ☐ All b)☐ Some * c)☐ None of:	der 35 U.S.C. § 119(a)-(d) or (f).					
	1. Certified copies of the priority documents have bee						
	2. Certified copies of the priority documents have bee						
	3. Copies of the certified copies of the priority documents have been received in this National Stage						
	application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.							
844b	des.						
Attachment	• •	A) The transfer Common (PTO 440)					
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) A) Interview Summary (PTO-413) Paper No(s)/Mail Date							
3) 🔲 Inform	mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) or No(s)/Mail Date	5) Notice of Informal Patent Application (PTO-152) 6) Other:					

Application/Control Number: 09/889,689

Art Unit: 1634

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

1. Group I, claims 6-9, drawn to isolated polynucleotides.

Group II, claims 10 and 11, drawn to a process for diagnosing the presence of a disease or colon cancer in a subject.

2. The inventions listed as Groups I-II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The special technical feature of Group I is considered to be one of SEQ ID NOS:1-6 that satisfies the expression $\mathbf{n_n} \leq \mathbf{x_n} - (\mathbf{x_n}^* \mathbf{y})$. However, Sulston et al. teach an isolated nucleic acid sequence of AC007032, BAC clone RP11-22N19 from 7q22, that with $\mathbf{n_n} = 5$, satisfies the above expression(see attached reference Genome Res. 8 (11), 1097-1108 (1998)). As the product of Group I does not represent a contribution over the prior art, the claims lack a special technical feature. Thus, the technical feature linking the recited groups I-II does not constitute a special technical feature as defined by PCT Rule 13.2, as it does not define a contribution over the prior art.

3. Further Restriction Requirement Applicable to All Groups:

Application/Control Number: 09/889,689

Art Unit: 1634

Additionally, each group named above is subject to a further restriction. Applicant is required to further elect a specific SEQ ID NO:, from 1-6. This is NOT an election of species. For example, if applicant elects group I, they must then further elect a single SEQ ID NO: for further prosecution. The same scenario exists for a group II election. Nucleotide sequences encoding different proteins are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute independent and distinct inventions within the meaning of 35 U.S.C 121. Absent evidence to the contrary, each such nucleotide sequences are presumed to represent an independent and distinct invention, subject to restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141. By statute, "[i]f two or more independent and distinct inventions are claimed in one application, the Commissioner may require the application to be restricted to one of the inventions." 35 U.S.C. 121. Pursuant to this statute, the rules provide that "[i]f two or more independent and distinct inventions are claimed in a single application, the examiner in his action shall require the applicant...to elect that invention to which his claims shall be restricted." 37 CFR 1.142 (a). See also 37 CFR 1.141(a).

The search and examination of all possible groups would pose an enormous burden on the examiner and on the PTO search resources. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as demonstrated by their recognized divergent subject matter due to SEQ ID NOS:1-6 that would require different searches that are not coextensive, examination of these claims would pose a serious burden on the examiner and therefore the restriction is deemed proper.

Application/Control Number: 09/889,689

Art Unit: 1634

Page 4

4. Applicant is advised that the reply to this requirement, to be complete, must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sally A Sakelaris whose telephone number is 571-272-0748. The examiner can normally be reached on M-Fri, 9-6:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Suly (mi 3/4/04

Supervisory Patent Examiner Technology Center 1600